Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

By S. Bowker, S. Majumdar, P. Veugelers, Jeffrey A. Johnson. Diabetes Care, 2006

1,022 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/de14be7d5562fdd34295934ddb59468523a86973

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Michael Pollak
2. G. Steinberg
3. M. V. Vander Heiden
4. R. Shaw
5. E. Gale
6. Bruce E. Kemp
7. B. Spiegelman

In Molecular Biology

1. R. Shaw
2. M. V. Vander Heiden
3. Michael Pollak
4. Ralph J. Deberardinis
5. Craig B. Thompson
6. G. Steinberg
7. Russell G. Jones
8. David M. Sabatini

In Surgery

1. Michael Pollak
2. R. Shaw
3. G. Steinberg
4. Ralph J. Deberardinis
5. Craig B. Thompson
6. M. V. Vander Heiden
7. Russell G. Jones
8. D. Alessi

Citations in the corpus

• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. (2006, background): “Indeed, the effects of metformin on these pathways in epithelial cells may be relevant to the recent preliminary observations from population studies suggesting that metformin administration reduces cancer risk (8) and mortality (9).”
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009, background): “Population studies have suggested that metformin decreases the incidence of cancer and cancer-related mortality in diabetic patients.(17,18) In addition, metformin has been shown to inhibit the growth of cancer cells, including breast cancer, in vitro(19-22) and of tumors in vivo.”
• GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). (2011, background): “For example, a cohort study using a large administrative database demonstrated an increased risk of cancer-related mortality in diabetic patients using sulfonylureas or insulin relative to metformin [22].”
• Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis (2014, neutral): “In several recent retrospective studies, investigators have observed an association between metformin use and diminished tumor progression in patients suffering from different types of cancers (Evans et al., 2005; Bowker et al., 2006; Dowling et al., 2012).”
• GRADE guidelines: 2. Framing the question and deciding on important outcomes. (2011, background): “For instance, an observational study found a previously unsuspected association between sulfonylurea use and cancer-related mortality [16].”
• Molecular mechanisms of cancer development in obesity (2011, background): “Additionally, cancer patients taking insulin or insulin secretagogues may have worse cancer outcomes than those taking metformin or TZD”
• New Users of Metformin Are at Low Risk of Incident Cancer (2009, background): “An independent epidemiological study found that users of sulfonylureas were at higher risk of cancer-related mortality than metformin users (7).”
• Insulin and insulin-like growth factor signalling in neoplasia (2008, background): “— might be associated with reduced cancer incidence and mortalit”
• Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. (2009, background): “The second mechanism is activated by IGF-II binding to IR-A/IR-B hybrids, which may have similar binding characteristics as IR-A homodimers (328).”
• Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. (2007, background): “(20) reported that type 2 diabetes patients who use metformin”
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes (2009, methodology): “Concomitant metformin was introduced as a covariate into the Cox models for the insulin-regimen subgroup since it has been reported to be associated with a reduced cancer risk [5, 6].”
• LKB1 and AMPK control of mTOR signalling and growth (2009, background): “Initial studies have revealed that diabetic patients taking metformin exhibit a statistical reduction in tumour incidence (Evans et al. 2005, Bowker et al. 2006).”
• AMPK in Health and Disease. (2009, background): “Since the constitutively active AMPK fragment 1 (1-312) is not activated by the PT1 compound, it is proposed that PT1 acts by reversing the autoinhibition of the AIS (313-335).”
• The LKB1-AMPK pathway: metabolism and growth control in tumor suppression (2009, neutral): “Initial studies showed that patients with diabetes taking metformin show a statistical reduction in tumour burden compared with patients taking any alternative dru”